Introduction
============

Autism as a syndrome was first described by Leo Kanner, a child psychologist, in 1943. His initial description, based on 11 case studies emphasized "...an innate inability to form the usual, biologically provided affective contact with other people." For a long time, autism was thought to be a consequence of bad parenting and the "refrigerator mother" theory (Bettelheim, [@B40]) lasted from the 1950s well beyond the 1970s. Bernard Rimland (Rimland, [@B177]) and Michael Rutter (Rutter, [@B189]) established empirically that the parents of autistic children were not different in their parenting from the parents of non-autistic controls and helped building a case for a neurobiological basis of autism. Autism is now recognized as a neurodevelopmental disorder manifesting within the first 3 years after birth and progressively worsening in the course of life. The core symptoms are impairments of sociability, communicative skills and imagination, together with stereotypic behaviors and repetitive tendencies (DSM-IV, [@B86]). At the cognitive level, all autistic children seem to display some form of abnormality in perception, attention, and memory (Ben Shalom, [@B36]; Dakin and Frith, [@B79]; Sanders et al., [@B192]).

Genetic analyses have revealed that autism is a polygenetic disorder where any one or more set of genes can predispose toward, but no one gene has been found to cause autism (Bonora et al., [@B45]; Cook, [@B66]; Lamb et al., [@B134]; Persico and Bourgeron, [@B166]). The primary cause of autism is most likely a form of epigenetic alteration during development (Beaudet and Zoghbi, [@B34]), which triggers a cascade of diverse neuropathologies depending on the timing of the epigenetic attack. A number of toxic insults have been implicated as the key triggers of autism (Bandim et al., [@B27]; Chess, [@B54]; Moore et al., [@B151]; Nanson, [@B158]; Rasalam et al., [@B173]; Stromland et al., [@B222]) (Table [1](#T1){ref-type="table"}) probably with a higher probability in the genetically predisposed.

###### 

**Potential environmental triggers for autism**.

  Teratogenic insult           Background                                                                                                                                                                                  Time of insult to cause ASD                                                                                                                                Disorder          Number of people studied (% ASD)   Study   Reference
  ---------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- ---------------------------------- ------- -----------------------------
  ***Infectious diseases***                                                                                                                                                                                                                                                                                                                                                                                                                        
  Maternal rubella infection   Infectious disease caused by the rubella virus                                                                                                                                              First 8 weeks of gestation                                                                                                                                 ASD, CRS          243 (7%)                           PS      Chess, [@B54]
                                                                                                                                                                                                                                                                                                                                                                                                                                           PS      Chess, [@B55]
                                                                                                                                                                                                                                                                                                                                                                                                                                           PS      Chess and Fernandez, [@B56]
  ***Drugs***                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Ethanol                      Prenatal alcohol exposure may cause FAS, which shares behavioural anomalies with autism                                                                                                     Unclear, animal studies suggest 3--5 week of gestation[^1^](#tbl1fn1){ref-type="table-fn"}                                                                 ASD, FAS          6                                  CR      Nanson, [@B158]
                                                                                                                                                                                                                                                                                                                                                                                                        3                                  CR      Harris et al., [@B107]
                                                                                                                                                                                                                                                                                                                                                                                                        24 (12.5%)                         PS      Aronson et al., [@B21]
  Misoprostol                  Produces a dose-related inhibition of gastric acid and pepsin secretion. Enhances mucosal resistance to injury. Effective anti-ulcer agent. Oxytocic properties. Used to induce abortion.                                                                                                                                                              ASD, MS           23 (26.1%)                         PS      Bandim et al., [@B27]
  Thalidomide                  Originally introduced as a non-barbiturate hypnotic, but was withdrawn from the market due to its\' teratogenic effects.                                                                    Days 20-24 of gestation                                                                                                                                    ASD, DS, FP, MS   87 (5.7%)                          PS      Stromland et al., [@B222]
  Valproic acid                Introduced as anticonvulsant and later mood-stabilizer primarily in the treatment of epilepsy and bipolar disorder; but also to treat migraine, headaches and schizophrenia.                Deduced to days 20--24 of gestation[^2^](#tbl1fn2){ref-type="table-fn"}, animal studies also suggest this time point[^3^](#tbl1fn3){ref-type="table-fn"}   ASD, FVS          19                                 PS      Ardinger et al., [@B19]
                                                                                                                                                                                                                                                                                                                                                                                                        1                                  CR      Christianson et al., [@B57]
                                                                                                                                                                                                                                                                                                                                                                                                        40                                 CR      Koch et al., [@B130]
                                                                                                                                                                                                                                                                                                                                                                                                        1                                  CR      Williams and Hersh, [@B238]
                                                                                                                                                                                                                                                                                                                                                                                                        57 (11%)                           PS      Moore et al., [@B151]
                                                                                                                                                                                                                                                                                                                                                                                                        5                                  CR      Williams et al., [@B237]
                                                                                                                                                                                                                                                                                                                                                                                                        77 (11.7%)                         PS      Rasalam et al., [@B173]

Abbreviations: ASD, autism spectrum disorder; CR, case report; CRS, congenital rubella syndrome; DS, Duane syndrome; FAS, fetal alcohol syndrome; FP, face paresis; FVS, fetal valproate syndrome; MS, Möbius syndrome; PS, population study.

^1^ Sulik et al., 1986.

^2^ Rodier et al., [@B183], [@B182]; Arndt, 2005.

^3^ Rodier et al., [@B183], [@B182]; Schneider and Przewlocki, [@B196]; Markram et al., [@B141].

Autism encompasses a spectrum of disorders ranging from severe mental retardation to high functioning Asperger\'s and "*idiots savants*" with many brain regions implicated making it difficult to develop a unified theory of autism. High functioning autism has been viewed as the exception to the mainstream view that autism is a severe form of mental retardation with poor cognitive capabilities (Lord and Spence, [@B138]; Pring, [@B170]). Indeed, of several hundred patents filed on "shot in the dark" treatments for autism, most are aimed at enhancing rather than reducing cognitive processes. However, a quite opposite scenario could be the case, in which the handicap may be resulting from excessive, rather than poor cognitive functioning.

Based on the recent multi-screening results obtained on the valproic acid (VPA) rat model of autism, we propose here a unifying hypothesis of autism where the core neurophysiological pathology is *excessive neuronal information processing and storage in local circuits of the brain*, which gives rise to hyper-functioning of the brain regions most affected. Such hyper-functioning in different brain regions is proposed to cause hyper-perception, hyper-attention, and hyper-memory that could potentially explain the full spectrum of symptoms in autism.

We propose that a common molecular syndrome is activated in autism that produces hyper-functioning in a coordinated manner by forming hyper-reactive and hyper-plastic microcircuits in different brain areas. The vast autism spectrum could be explained by the specific degree to which this hyper-functional molecular syndrome is active in different brain areas, which could depend on the precise stage of development that the brain is exposed to a triggering insult, the type of toxic insult, and the presence of any predisposing genes.

We propose that these super-charged microcircuits render aspects of the world painfully intense and aversive, and autism is therefore proposed as an *Intense World Syndrome*. We present recent molecular, cellular, synaptic, circuit, and behavioral evidence to support this new hypothesis and re-interpret the symptomology and pathology in the light of the proposed syndrome in which the world is aversively intense.

Heterogeneity in the Autistic Syndrome
======================================

The major problem in developing a unifying theory of autism is the large number of variations of the disorder. The heterogeneity is so extreme that at least five behavioral subtypes are classified as part of the autism spectrum disorders (ASD) -- autistic disorder, Asperger\'s syndrome, Rett\'s syndrome, disintegrative disorder, and pervasive developmental disorder (PDD) not otherwise specified. According to the DSM-IV, a triad of symptoms, impaired social interactions, communication deficits as well as stereotypic, restricted, and repetitive behaviors, characterizes all these subtypes of autism.

Heterogeneity further manifests within each of the three core symptoms. In the social domain, inter-individual variability may range from a complete absence of interest in interacting with others, to more subtle dysfunctions in managing complex social interactions, in which other peoples\' intentions or the social context need to be taken into account. Communication impairments may range from a complete absence of spoken language over mild impairment, with the use of idiosyncratic vocabulary, to hyper-linguism in some of the Asperger cases. Stereotyped behaviors may also range from simple motor stereotypies and a preference for sameness to more complex rituals, which may be accompanied by considerable distress and aggression when they cannot be fulfilled.

Intellectual capabilities also vary across the entire IQ spectrum with the majority of autistic individuals displaying very low IQs and the high functioning savants coming out on the other extreme high end of the IQ spectrum. The communication handicap, however, confounds the accurate assessment of IQ in autists and numerous anecdotal reports suggest that when the communication deficits are solved in some way (e.g., through communication devices), unusually high IQ\'s are revealed. Moreover, some individuals exhibit truly high intellectual capabilities and excellent achievements in highly specialized fields of interest (Asperger, [@B22]; Pring, [@B170]).

Comorbidities
=============

Austistic symptoms are found in association with many other disorders. Roughly 30% of autistic individuals develop clinically apparent seizures, suggesting certain imbalances in cortical circuits. Other comorbidities include neurofibromatosis, congenital rubella, hydrocephalus, ambulation, fetal alcohol syndrome and Fragile X syndrome, (Lord and Spence, [@B138]).

Estimates of the frequency of such problems and conclusions about the nature of the association have differed from one research group to another (Gillberg and Coleman, [@B97]; Rutter et al., [@B191]). Studies that consider these comorbidities as subtypes of autism and use these disorders as the basis for developing genetic models of autism have contributed conflicting results (Hayashi et al., [@B108]; Tabuchi et al., [@B224]), which have confounded a coherent picture of the core pathologies underlying autism.

Understanding the Common Cause of Autism
========================================

Autism is recognized as one of the most heritable neuropsychiatric disorders, since the concordance rates of autism in monozygotic twins are above 60%, whereas sibling risk is around 2--7%, which is much higher than in the general population (0.01--0.08%) (Bailey et al., [@B25]; Bonora et al., [@B45]; Hallmayer et al., [@B104]; Le Couteur et al., [@B136]; Rutter, [@B190]; Spiker et al., [@B217]). The mode of inheritance seems to be complex, since up to 15 different chromosomal loci have been identified in producing the risk (Bonora et al., [@B45]; Cook, [@B66]; Lamb et al., [@B134]; Persico and Bourgeron, [@B166]). Many of these loci encode molecules and proteins, which have been linked to neurodevelopment and synaptic function (Cook, [@B66]; Lamb et al., [@B134]; Persico and Bourgeron, [@B166]). Not all children with predisposing genes develop autism indicating that the genetic alterations should not be seen as the cause of autism, but as a major predisposing factor.

Autism is a neurodevelopmental disorder suggesting that there is a relatively narrow time window during embryogenesis (perhaps extending into early postnatal life), during which the normal unfolding of the genome can be sabotaged by an epigenetic attack. Evidence has accumulated that toxic exposure during early embryogenesis and/or very early after birth can trigger the onset of autism. In the extreme view, autism may even result from such epigenetic insults without predisposing genes, but with a lower probability. Some potent teratogens include maternal rubella infection (Chess, [@B54]), ethanol (Nanson, [@B158]), misoprostol (Bandim et al., [@B27]), thalidomide (Stromland et al., [@B222]), and VPA (Moore et al., [@B151]; Rasalam et al., [@B173]) (summarized in Table [1](#T1){ref-type="table"}). The most vulnerable period of exposure seems to be the first trimester of gestation (Arndt et al., [@B20]).

Understanding the ultimate cause of autism lies in understanding the nature of the epigenetic attack and developing the ultimate cure for autism lies in being able to prevent this attack and reverse its\' effects once it has occurred. The particular form of the attack may give rise to a syndrome with very diverse outcomes and reconciling these diverse outcomes under a common cascade of effects (if one such cascade exists) is crucial to both understanding the cause and developing the for autism.

Animal Models of Autism
=======================

Autism is generally considered a human disorder because of the high level cognitive symptomology in the domain of social interaction, communication, and theory of mind. This conclusion is, however, unjustified and there is no reason to believe that the core neurophysiological pathology that occurs in humans cannot also occur in other mammals. Monkeys are more easily related to the human condition, but rodents also exhibit complex social systems and rich social interactions, and many cognitive functions can be studied such as perception, attention, memory, and emotions. Specific tasks targeted at unraveling "autistic" symptoms have been designed and tested in several rodent models (Crawley, [@B77]). It is of course not possible to study all the subtleties of the disorder using animal models, but they provide a scope of research just not possible in humans and in many cases also not possible in monkeys. Rodent models in particular allow an extensive multi-omics approach to autism with a spectrum of non-invasive and invasive approaches at the genetic, molecular, cellular, synaptic, local circuit, circuit, systems, and behavioral levels. Ultimately, all neuropsychiatric and neurological disorders are due to some type of dysfunction in the manner in which neurons process information and to understand this dysfunction requires invasive electrophysiological experiments, which cannot be studied in humans.

There are three types of animal models of autism -- genetically based, insult-based, and lesion-based models. Genetically based models assume that a specific gene can cause the disorder and the hypothesis is explored typically in mice by knocking out the gene or by engineering subtle mutations. An example of a genetically based model of autism is the oxytocin knockout mouse (Winslow and Insel, [@B240]). Insult-based models such as the VPA model (Rodier et al., [@B182]), examine the teratogenic effect with the assumption that the insult alone is sufficient to trigger the disorder. Lesion-based models damage a specific part of the brain hypothesized to be involved in an aspect of causing autism and an example is amygdala lesions in monkeys (Bachevalier, [@B23]). Future models may begin to combine genetically predisposed models with insult-based approaches. The advantage of the insult-based models is that the neurodevelopmental disorder which emerges is independent of the genetic predisposition allowing the systematic study of core abnormal brain and behavior developmental cascade that is triggered from the moment of the epigenetic attack to the matured animal.

The next chapter concentrates on the insult-based VPA rat model of autism, as this model is one of the best studied and validated models, and has allowed us to perform extensive multi-omics studies that yield a more comprehensive view of the induced disorder.

VPA Exposure in Humans
======================

Clinically, VPA was first introduced in 1964 in France as an anticonvulsant and later as a mood-stabilizing drug, primarily in the treatment of epilepsy and bipolar disorder, but also used for migraine headaches and schizophrenia. In epileptics, VPA is used to control absence seizures, tonic-clonic seizures, complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome. VPA use during pregnancy has been linked to autism.

Studies implicating VPA in autism
---------------------------------

The first indications for VPA to cause autism stems from seven case studies of kids with fetal valproate syndrome (Christianson et al., [@B57]; Williams and Hersh, [@B238]; Williams et al., [@B237]), of which all exhibited a full diagnosis of autism. Moore and colleagues conducted the first population study on 57 children with various fetal anticonvulsant syndromes (caused by a variety of anticonvulsant drugs) in Scotland (Moore et al., [@B151]). These all children had been exposed to either VPA alone (60%), VPA in combination with another anticonvulsant drug (21%), or another anticonvulsant drug (carbamezepine or phenytoin) alone or in combination with each other (19%). They reported 46 (81%) kids with speech delays and 34 (60%) kids with two or more autistic features, of which 6 (11%) had a diagnosis of ASD. Furthermore, 46 (81%) had behavioral problems, 22 (39%) displayed hyper-activity or poor concentration, of which 4 (7%) had a diagnosis of attention deficit/hyper-activity disorder. Forty-four (77%) kids had learning difficulties, 34 (60%) had gross motor delay, and 24 (42%) had fine motor delay. These findings confirmed the association between fetal valproate syndrome and autism as suggested in the prior case reports. A more recent longitudinal population study spanning a period of 20 years examined 292 children whose mothers were exposed to antiepileptic drugs during pregnancy (Rasalam et al., [@B173]). Out of this population, 56 children were exposed to VPA alone and 77 children to VPA alone or in combination with another antiepileptic drug. Among these two sub-populations, 5 (8.9%) and 9 (11.7%) children fulfilled the criteria for ASD, respectively (Rasalam et al., [@B173]). Both population studies indicate that the rate of autism in the prenatally VPA-exposed population is much higher than the estimated rate of ASD in the general population of approximately 10 to 16 cases per 10.000 (Fombonne, [@B91]).

VPA, thalidomide, and the early brain-stem injury hypothesis
------------------------------------------------------------

The malformations caused by VPA and thalidomide, another autism causing teratogen, indicate an early insult during embryogenesis and, more specifically, around the time of neural tube closure, which led to the hypothesis that autism may be caused by a brain-stem injury during embryonic development (Arndt et al., [@B20]; Rodier et al., [@B183]; Rodier et al., [@B182]; Stromland et al., [@B222]). First indications for this hypothesis stem form a Swedish thalidomide study (Stromland et al., [@B222]) in which 87 patients were examined with the initial purpose of evaluating ophthalmologic effects, but a psychiatric evaluation was also performed. Five cases with autism were found in this study. All of these cases were from a group of 15 patients where thalidomide exposure occurred between the 20th--24th days of gestation while no autistic cases were reported for any other exposure times. The probability of autism after thalidomide exposure during this time period is, therefore, extremely high.

This period of gestation is when the neural tube closes and the first neurons are produced. These neurons are part of the motor nuclei of the cranial nerves and an insult affecting these neurons, therefore, is associated with abnormalities in facial features - indeed observed in all of the five autistic thalidomide cases. Three patients had Duane syndrome (failure of the VIth/abducens cranial nerve to innervate the lateral rectus muscle by the eye with subsequent reinnervation of the muscle by the IIIrd/oculomotor cranial nerve); one patient had face paresis (oculomotor palsy); four had Möbius syndrome (failure of the VIIth/facial cranial nerve to innervate the facial muscles); two had abnormal lacrimation (due to a failure of the neurons of the superior salivatory nucleus -- cranial nerve VII -- to innervate the lacrimal apparatus). All five patients had ear malformations and hearing deficits. Ear malformations (Walker, [@B233]), eye motility problems (Scharre and Creedon, [@B195]), and Mobius syndrome (Gillberg and Steffenburg, [@B96]) had previously been associated with autism. In fact, external ear malformation is the most common physical abnormality observed in autism and the one which best distinguishes between autism and mental retardation (Walker, [@B233]). The conclusion from this thalidomide study was that autism is associated with a brainstem injury at a very specific time during embryogenesis.

Some of the teratogentic effects of VPA resemble those of thalidomide. These include the same neural tube closure defects such as facial dysmorphy and ear abnormalities. Even though VPA, as a remedy for epilepsy, is usually taken throughout the entire pregnancy, the time point of injury can be deduced on the basis of these physical malformations. Since these are very similar to the thalidomide-induced autistic cases and the exact time period for thalidomide to cause autism is known to be between embryonic days (EDs) 20--24 (Stromland et al., [@B222]), it has been argued that the time point of VPA to cause autism is the same as for thalidomide (Rodier et al., [@B183]; Rodier et al., [@B182]).

In order to test the brain-stem hypothesis of autism, the brain of an autistic person, never exposed to thalidomide or VPA, was examined for brain-stem injuries and compared to a healthy brain (Rodier et al., [@B183]). It turned out that the brain stem of the autistic brain exhibited a severe loss of motor neurons in the facial nucleus. Whereas the facial nucleus in the healthy brain contained more than 9000 neurons, in the autistic brain only 400 neurons were present in this area. The superior olive, an auditory relay nucleus, was also missing completely, further supporting the brain-stem association in autism. This study further indicated that brain-stem injuries indeed occur in autism.

The early brain-stem hypothesis of autism states that all other brain defects observed in autism must be a consequence of this one early brain-stem injury -- a big bang -- since no other brain regions are yet developed (Rodier et al., [@B183]). It is, however, possible that progenitor cells for other brain regions may also be affected and the damage produced would only become obvious once these regions begin to develop. It is also not yet clear whether other brain regions may be vulnerable to a VPA insult at later stages of development, i.e., whether each brain region has its own vulnerability to VPA exposure at the moment of its first differentiation.

VPA Exposure in Rats
====================

In order to prove the hypothesis that an early brain-stem injury may provoke the same pattern of overall brain anomalies as observed in autism, an animal model was developed (Rodier et al., [@B183]). VPA was the drug of choice, since thalidomide has different effects in rodents than in humans (Schumacher et al., [@B203]). VPA, on the other hand, is a powerful teratogen in rodents and produces many of the malformations observed in humans (Binkerd et al., [@B41]; Collins et al., [@B65]; Ehlers et al., [@B88]). The time of neural tube closure in the rat occurs on day 11.5 and within the 12th day of gestation, production of the motor nuclei of trigeminal, abducens, and hypoglossal nerves is completed (Altman and Bayer, [@B13]). A single dose of VPA (350 mg/kg) administered to pregnant dams on ED 11.5 resulted in a reduction of the trigeminal and hypoglossal motor nuclei. Exposure on ED12 caused an additional loss of neurons in the abducens nucleus and on ED12.5 in all the previous and additionally in the oculomotor nucleus (Table [2](#T2){ref-type="table"}; Rodier et al., [@B183]).

###### 

**Anatomical and morphological alterations in the VPA rat model of autism**.

  Neuron                          Measurement                                     ROI                         Effect           Gender   Dose (mg/kg)   ED VPA admin   PND testing   Reference
  ------------------------------- ----------------------------------------------- --------------------------- ---------------- -------- -------------- -------------- ------------- -------------------------
  ***Anatomy and morphology***                                                                                                                                                      
  Motor neurons                   Cell number                                     Trigeminal Ncl              Reduced          M, F     350            11.5           11            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Trigeminal Ncl              Reduced          M, F     350            12             11            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Trigeminal Ncl              Reduced          M, F     350            12.5           10            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Trigeminal Ncl              No effect        M, F     350            12.5           60            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Hypoglossal Ncl             Reduced          M, F     350            11.5           11            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Hypoglossal Ncl             Reduced          M, F     350            12             11            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Hypoglossal Ncl             Reduced          M, F     350            12.5           10            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Hypoglossal Ncl             Reduced          M, F     350            12.5           60            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Abducens Ncl                No effect        M, F     350            11.5           11            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Abducens Ncl                Reduced          M, F     350            12             11            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Abducens Ncl                Reduced          M, F     350            12.5           10            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Abducens Ncl                No effect        M, F     350            12.5           60            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Oculomotor Ncl              No effect        M, F     350            11.5           11            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Oculomotor Ncl              No effect        M, F     350            12             11            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Oculomotor Ncl              Reduced          M, F     350            12.5           10            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Oculomotor Ncl              Reduced          M, F     350            12.5           60            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Facial Ncl                  No effect        M, F     350            11.5           11            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Facial Ncl                  No effect        M, F     350            12             11            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Facial Ncl                  No effect        M, F     350            12.5           10            Rodier et al., [@B183]
  Motor neurons                   Cell number                                     Facial Ncl                  No effect        M, F     350            12.5           60            Rodier et al., [@B183]
  Neurons                         Cell number                                     Mesencephalic Ncl of CN V   No effect        M, F     350            11, 12, 12.5   10            Rodier et al., [@B183]
  Neurons                         Cell number                                     Locus coeruleus             No effect        M, F     350            11, 12, 12.5   10            Rodier et al., [@B183]
  Neurons                         Cell number                                     Dorsal motor Ncl of CN X    No effect        M, F     350            11, 12, 12.5   10            Rodier et al., [@B183]
  Purkinje cells                  Cell number                                     Cb-vermis                   Reduced          M, F     600            12.5           40            Ingram et al., [@B122]
  Purkinje cells                  Cell number                                     Cb-hemisphere               No effect        M, F     600            12.5           40            Ingram et al., [@B122]
  Pyramidal neurons               Cell number                                     S1                          No effect        M        500            12.5           12--16        Rinaldi et al., [@B178]
  Pyramidal neurons               Gross somatic, axonal and dendritic structure   S1                          No effect        M        500            12.5           12--16        Rinaldi et al., [@B178]
  Pyramidal neurons               Spine and bouton density                        S1                          No effect        M        500            12.5           12--16        Rinaldi et al., [@B178]
  Pyramidal neurons               Synaptic contact number                         S1                          Reduced by 40%   M        500            12.5           12--16        Rinaldi et al., [@B178]
  Pyramidal neurons               Apoptosis                                       S1                          No effect        M        500            12.5           12--16        Rinaldi et al., [@B178]
  ***Brain volume and weight***                                                                                                                                                     
                                  Volume                                          Overall                     Reduced          M, F     600            12.5           40            Ingram et al., [@B122]
                                  Volume                                          Cb-vermis                   Reduced          M, F     600            12.5           40            Ingram et al., [@B122]
                                  Volume                                          Cb-hemisphere               Reduced          M, F     600            12.5           40            Ingram et al., [@B122]
                                  Cell density                                    Cb-vermis                   No effect        M, F     600            12.5           40            Ingram et al., [@B122]
                                  Cell density                                    Cb-hemisphere               No effect        M, F     600            12.5           40            Ingram et al., [@B122]
                                  Weight                                          Overall                     Reduced          M, F     350            12.5           10            Rodier et al., [@B183]
                                  Weight                                          Overall                     Reduced          M, F     350            12.5           60            Rodier et al., [@B183]

Results describe the VPA-treated offspring group relative to controls. All studies were performed on rats. Abbreviations: ED, embryonic day; F, female; M, male; N, number; Ncl, nucleus; PND, postnatal day; ROI, region of interest; VPA, valproic acid. ROI: Cb, cerebellum; CN, cranial nerve; S1, primary sensory cortex.

Follow-up anatomical studies showed that VPA exposure on ED12.5 also results in a loss of cerebellar neurons (Ingram et al., [@B122]; Rodier et al., [@B182]), one of the most prominent features in the autistic brain (Kemper and Bauman, [@B125]; Palmen et al., [@B162]; Ritvo et al., [@B181]). Purkinje cells were particularly reduced in the lobules VI--VIII and IX, but not the anterior lobules (IV and V) of the vermis. Moreover, the nucleus interpositus (corresponding to the globose and emboliform nuclei in humans) was smaller. These early experimental studies were able to prove that a single dose of VPA may cause the same neural tube closure injuries as observed after thalidomide and VPA exposure in humans as well as in autism.

More recently, the serotonergic system was studied in VPA-treated rat offspring (Miyazaki et al., [@B150]; Narita et al., [@B159]; Tsujino et al., [@B229]) (Table [3](#T3){ref-type="table"}). Administration of a single dose of VPA on ED9 (neural plate stage) has also been found to dramatically increase the serotonin levels in the blood as well as the frontal cortex, hippocampus, and cerebellum (Narita et al., [@B159]; Tsujino et al., [@B229]). VPA administration also irreversibly altered serotonergic neuronal differentiation and migration in the dorsal Raphé nucleus (Miyazaki et al., [@B150]; Tsujino et al., [@B229]). These results are strikingly similar to the data obtained on the serotonergic system in human autism (Lam et al., [@B133]), discussed further below.

###### 

**Neurochemical and genetic alterations in the VPA rat model of autism**.

  Neurochemical system                    Measurement                ROI                     Effect                          Dose (mg/kg)   ED VPA admin   PND testing              Reference
  --------------------------------------- -------------------------- ----------------------- ------------------------------- -------------- -------------- ------------------------ --------------------------
  ***Monamines***                                                                                                                                                                   
  Dopamin                                 expression                 Frontal cortex          Enhanced                        800            9              35                       Narita et al., [@B159]
  Serotonin                               5-HT expression            Frontal cortex          Enhanced                        800            9              56--105                  Tsujino et al., [@B229]
  Serotonin                               5-HT expression            Frontal cortex          No effect                       800            9              50                       Narita et al., [@B159]
  Serotonin                               5-HT expression            Hippocampus             Enhanced                        800            9              50                       Narita et al., [@B159]
  Serotonin                               5-HT expression            Cerebellum              Enhanced                        800            9              50                       Narita et al., [@B159]
  Serotonin                               5-HT expression            Medulla                 No effect                       800            9              50                       Narita et al., [@B159]
  Serotonin                               5-HT expression            Plasma                  Enhanced                        800            9              50                       Narita et al., [@B159]
  Serotonin                               5-HT positive cell count   dR, overall             No effect                       800            9              50                       Miyazaki et al., [@B150]
  Serotonin                               5-HT positive cell count   dR, overall             Enhanced, but not significant   800            9              91, 119                  Tsujino et al., [@B229]
  Serotonin                               5-HT positive cell count   dR, rostral to caudal   Enhanced caudally               800            9              50                       Miyazaki et al., [@B150]
  Serotonin                               5-HT positive cell count   dR, rostral to caudal   Enhanced caudally               800            9              91, 119                  Tsujino et al., [@B229]
  ***Excitatory amino acid receptors***                                                                                                                                             
  AMPAR                                   GluR1 expression           S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  AMPAR                                   GluR2 expression           S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  AMPAR                                   GluR3 expression           S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  AMPAR                                   pGluR1-S831 expression     S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  AMPAR                                   pGluR1-S845 expression     S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  NMDAR                                   NR1 expression             S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  NMDAR                                   NR2A expression            S1                      Enhanced                        500            12.5           12--16                   Rinaldi et al., [@B179]
  NMDAR                                   NR2B expression            S1                      Enhanced                        500            12.5           12--16                   Rinaldi et al., [@B179]
  NMDAR                                   pNR1-S896 expression       S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  NMDAR                                   pNR1-S897 expression       S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  NMDAR                                   pNR2B-S1303 expression     S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  mGluR                                   mGluR1 expression          S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  mGluR                                   mGluR5 expression          S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  mGluR                                   mGluR4 expression          S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  mGluR                                   mGluR6/7 expression        S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  Kainate receptor                        GluR6/7 expression         S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  ***Synaptic plasticity molecules***                                                                                                                                               
  CREB                                    expression                 S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  pCREB-S133                              expression                 S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  CamKII                                  expression                 S1                      Enhanced                        500            12.5           12--16                   Rinaldi et al., [@B179]
  pCamKII-T286/287                        expression                 S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  ERK                                     expression                 S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  perk-Thr202/Tyr204                      expression                 S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  ***Endogenous opioids***                                                                                                                                                          
  Enkephalin                              PENK mRNA expression       CeA                     No effect                       600            12.5           60--90                   Schneider et al., 2007
  Enkephalin                              PENK mRNA expression       Dorsal striatum         Reduced                         600            12.5           60--90                   Schneider et al., 2007
  Enkephalin                              PENK mRNA expression       Ncl accumbens           Reduced                         600            12.5           60--90                   Schneider et al., 2007
  ***Cyptosceleton***                                                                                                                                                               
  β-Actin                                 expression                 S1                      No effect                       500            12.5           12--16                   Rinaldi et al., [@B179]
  ***Genes involved in development***                                                                                                                                               
  Shh                                     mRNA expression            Whole embryo            Reduced                         800            9              GD 11                    Miyazaki et al., [@B150]
  Hoxa1                                   mRNA expression            Whole embryo            Enhanced on GD 10, 12, 13, 14   600            10, 12--15     1 hours post-treatment   Stodgell et al., [@B221]
  Hoxa1                                   mRNA expression            Brain stem              Enhanced                        600            12.5           2 hours post-treatment   Stodgell et al., [@B221]

Results describe the VPA-treated offspring group relative to controls. All studies were performed on male rats. Abbreviations: AMPAR, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; CamKII, calcium-calmodulin-dependent protein kinase type 2; CREB, cAMP response element binding protein; ERK, extracellular signal-regulated kinase; ED, embryonic day; F, female; M, male; mGluR, metabotropic glutamate receptor; mRNA, messenger ribonucleic acid; N, number; NMDAR, N-Methylaspartate receptor; PENK, proenkephalin; PND, postnatal day; ROI, region of interest; shh, sonic hedgehog; VPA, valproic acid. ROI: CeA, central nucleus amygdala; dR, dorsal raphe nucleus; S1, primary sensory cortex.

At the behavioral level, it was already known for some time that VPA may cause severe and selective alterations in the offspring when administered throughout pregnancy (Vorhees, [@B231],[@B230]; Wagner et al., [@B232]), summarized in Table [4](#T4){ref-type="table"}. However, these behavioral alterations may also reflect other teratogenic effects induced by prolonged VPA exposure. Therefore, it is more advantageous to test animals which received a single injection at ED12.5 as proposed by Rodier et al. ([@B183]), since this model offers a specific hypothesis about the genesis of autism and has been validated on anatomical and proteomic grounds. Offspring of pregnant dams exposed to VPA during this period exhibited decreased social interactions, increased repetitive behaviors, enhanced anxiety, locomotor hyper-activity, lower sensitivity to pain, higher sensitivity to non-painful sensory stimulation, impaired pre-pulse inhibition, and enhanced eye-blink conditioning (Markram et al., [@B141]; Schneider and Przewlocki, [@B196]; Schneider et al., [@B197]; Schneider et al., [@B198]; Stanton et al., [@B218]) -- symptoms described in the DSM-IV and in the autism literature (DSM-IV, [@B86]; McAlonan et al., [@B142]; Muris et al., [@B157]; Perry et al., [@B165]; Sears et al., [@B206]). All results obtained on the VPA rodent model of autism are summarized in Tables [2--5](#T2 T3 T4 T5){ref-type="table"}.

###### 

**Behavioural alterations in the VPA rat model of autism**.

  Function                                                                                     Task                                        Effect                     Species   Gender   Dose (mg/kg)   GD VPA admin   PND testing      Reference
  -------------------------------------------------------------------------------------------- ------------------------------------------- -------------------------- --------- -------- -------------- -------------- ---------------- -----------------------------------
  ***Motor development, locomotion, vestibular function (focal prenatal VPA exposure)***                                                                                                                                                
  Vestibular function, motor development,                                                      Negative geotaxis                           No effect                  Rat       M        600            12.5           7--10            Schneider and Przewlocki, [@B196]
  Vestibular function, motor development,                                                      Negative geotaxis                           No effect                  Mouse     M, F     600            13             13--19           Wagner et al., [@B232]
  Motor development                                                                            Surface righting                            Impaired                   Mouse     M, F     600            13             5--9             Wagner et al., [@B232]
  Motor development                                                                            Mid-air righting                            Impaired                   Mouse     M, F     600            13             13--19           Wagner et al., [@B232]
  Motor development                                                                            Hanging wire grip strength                  Enhanced                   Mouse     M, F     200            13             13--19           Wagner et al., [@B232]
  Motor development                                                                            Balance beam                                No effect                  Mouse     M, F     600            13             20--26           Wagner et al., [@B232]
  Motor development                                                                            Swim performance                            Impaired                   Rat       M        600            12.5           8, 12            Schneider and Przewlocki, [@B196]
  Motor development                                                                            Swim performance                            No effect                  Rat       M        600            12.5           10, 16           Schneider and Przewlocki, [@B196]
  Locomotion                                                                                   Open field                                  Enhanced                   Rat                800            9              18               Tsujino et al., [@B229]
  Locomotion                                                                                   Opto-Varimex cage                           Enhanced                   Rat       M        600            12.5           30--50           Schneider and Przewlocki, [@B196]
  Locomotion                                                                                   Opto-Varimex cage                           Enhanced                   Rat       M        600            12.5           90--120          Schneider and Przewlocki, [@B196]
  Locomotion                                                                                   Plexi-glass box                             Enhanced                   Mouse     M, F     600            13             20--26           Wagner et al., [@B232]
  Locomotion                                                                                   EPM                                         No effect                  Rat       M, F     500            12.5           110--120         Markram et al., [@B141]
  ***Motor development, locomotion, vestibular function (prolonged prenatal VPA exposure)***                                                                                                                                            
  Vestibular function, motor development                                                       Negative geotaxis                           Impaired                   Mouse     M, F     200            12--17         13--19           Wagner et al., [@B232]
  Motor development                                                                            Surface righting                            No effect                  Mouse     M, F     200            12--17         5--9             Wagner et al., [@B232]
  Motor development                                                                            Mid-air righting                            No effect                  Mouse     M, F     200            12--17         13--19           Wagner et al., [@B232]
  Motor development                                                                            Hanging wire grip strength                  No effect                  Mouse     M, F     200            12--17         13--19           Wagner et al., [@B232]
  Motor development                                                                            Balance beam                                No effect                  Mouse     M, F     200            12--17         20--26           Wagner et al., [@B232]
  Motor development                                                                            Swim performance                            No effect                  Rat       M, F     150            7--18          50               Vorhees, [@B230]
  Motor development                                                                            Swim performance                            Impaired                   Rat       M, F     200            7--18          50               Vorhees, [@B230]
  Locomotion                                                                                   Activity meter                              No effect                  Rat       M, F     150            7--18          7,9, 11          Vorhees, [@B230]
  Locomotion                                                                                   Activity meter                              No effect                  Rat       M, F     200            7--18          7,9, 11          Vorhees, [@B230]
  Locomotion                                                                                   Open field                                  No effect                  Rat       M, F     150            7--18          40--42           Vorhees, [@B230]
  Locomotion                                                                                   Open field                                  No effect                  Rat       M, F     200            7--18          40--42           Vorhees, [@B230]
  Locomotion                                                                                   Plexi-glass box                             No effect                  M         M, F     200            12--17         20--26           Wagner et al., [@B232]
  ***Exploration (focal prenatal VPA exposure)***                                                                                                                                                                                       
  Exploration                                                                                  Hole board                                  Reduced                    Rat       M        600            12.5           30--50           Schneider and Przewlocki, [@B196]
  Exploration                                                                                  Hole board                                  Reduced                    Rat       M        600            12.5           90--120          Schneider and Przewlocki, [@B196]
  ***Exploration (prolonged prenatal VPA exposure)***                                                                                                                                                                                   
  Activity, Eploration                                                                         Figure 8                                    No effect                  Rat       M, F     150            7--18          40--42           Vorhees, [@B230]
  Activity, Eploration                                                                         Figure 8                                    No effect                  Rat       M, F     200            7--18          40--42           Vorhees, [@B230]
  Eploration                                                                                   Hole board                                  Enhanced                   Rat       M, F     150            7--18          45               Vorhees, [@B230]
  Eploration                                                                                   Hole board                                  Reduced                    Rat       M, F     200            7--18          45               Vorhees, [@B230]
  ***Circadian Rhythm***                                                                                                                                                                                                                
  Locomotion under 12 hours light/dark cycle                                                   Plastic cages                               Enhanced in light phase    Rat                800            9              28--43           Tsujino et al., [@B229]
  Feeding under 12 hours light/dark cycle                                                      Plastic cages                               Impaired cycle variation   Rat                800            9              28--43           Tsujino et al., [@B229]
  ***Perception (focal prenatal VPA exposure)***                                                                                                                                                                                        
  Olfactory                                                                                    Olfactory discrimination, nest seeking      Impaired                   Rat       M        600            12.5           9                Schneider et al., [@B197]
  Olfactory                                                                                    Olfactory discrimination, nest seeking      No effect                  Rat       M        600            12.5           10, 11           Schneider and Przewlocki, [@B196]
  Tactile                                                                                      Von Frey test                               Enhanced                   Rat       M        600            12.5           30--50           Schneider and Przewlocki, [@B196]
  Tactile                                                                                      Von Frey test                               No effect                  Rat       M        600            12.5           90--120          Schneider and Przewlocki, [@B196]
  Auditory                                                                                     Auditory startle                            No effect                  Rat       M        600            12.5           30--50           Schneider and Przewlocki, [@B196]
  Auditory                                                                                     Auditory startle                            No effect                  Rat       M        600            12.5           90--120          Schneider and Przewlocki, [@B196]
  Auditory                                                                                     Auditory startle                            No effect                  Rat       M, F     500            12.5           80--90           Markram et al., [@B141]
  Sensori-motor gating                                                                         PPI                                         Reduced                    Rat       M        600            12.5           30--50           Schneider and Przewlocki, [@B196]
  Sensori-motor gating                                                                         PPI                                         Reduced                    Rat       M        600            12.5           90--120          Schneider and Przewlocki, [@B196]
  Sensori-motor gating                                                                         PPI                                         Reduced                    Rat       M, F     500            12.5           80--90           Markram et al., [@B141]
  ***Perception (prolonged prenatal VPA exposure)***                                                                                                                                                                                    
  Auditory                                                                                     Auditory startle                            No effect                  Rat       M, F     150            7--18          85               Vorhees, [@B230]
  Auditory                                                                                     Auditory startle                            Reduced                    Rat       M, F     200            7--18          85               Vorhees, [@B230]
  Tactile                                                                                      Air-puff startle                            No effect                  Rat       M, F     150            7--18          85               Vorhees, [@B230]
  Tactile                                                                                      Air-puff startle                            Reduced                    Rat       M, F     200            7--18          85               Vorhees, [@B230]
  ***Nociception (focal prenatal VPA exposure)***                                                                                                                                                                                       
  Tactile                                                                                      Tail flick                                  Reduced                    Rat       M        600            12.5           \<30             Schneider et al., [@B197]
  Tactile                                                                                      Tail flick                                  Reduced                    Rat       M        600            12.5           30--50           Schneider and Przewlocki, [@B196]
  Tactile                                                                                      Tail flick                                  Reduced                    Rat       M        600            12.5           90--120          Schneider and Przewlocki, [@B196]
  Tactile                                                                                      Tail flick                                  Reduced                    Rat       M        600            12.5           \>90             Schneider et al., [@B197]
  Thermal                                                                                      Hot plate                                   No effect                  Rat       M        600            12.5           \<30             Schneider et al., [@B197]
  Thermal                                                                                      Hot plate                                   Reduced                    Rat       M        600            12.5           30--50           Schneider and Przewlocki, [@B196]
  Thermal                                                                                      Hot plate                                   Reduced                    Rat       M        600            12.5           90--120          Schneider and Przewlocki, [@B196]
  Thermal                                                                                      Hot plate                                   Reduced                    Rat       M        600            12.5           \>90             Schneider et al., [@B197]
  Thermal                                                                                      Hot plate                                   Reduced                    Rat       M, F     500            12.5           80--90           Markram et al., [@B141]
  ***Anxiety (focal prenatal VPA exposure)***                                                                                                                                                                                           
  Anxiety                                                                                      EPM                                         Enhanced                   Rat       M        600            12.5           30--50           Schneider et al., [@B198]
  Anxiety                                                                                      EPM                                         Enhanced                   Rat       M        600            12.5           60--90           Schneider et al., 2007
  Anxiety                                                                                      EPM                                         Enhanced                   Rat       M        600            12.5           90--120          Schneider et al., [@B198]
  Anxiety                                                                                      EPM                                         Enhanced                   Rat       M, F     500            12.5           110--120         Markram et al., [@B141]
  ***Anxiety (prolonged prenatal VPA exposure)***                                                                                                                                                                                       
  Anxiety                                                                                      Open field                                  No effect                  Rat       M, F     150            7--18          40--42           Vorhees, [@B230]
  Anxiety                                                                                      Open field                                  Enhanced                   Rat       M, F     200            7--18          40--42           Vorhees, [@B230]
  ***Social behaviours (focal prenatal VPA exposure)***                                                                                                                                                                                 
  Social behaviour                                                                             Free interaction                            Impaired                   Rat       M        600            12.5           30--50           Schneider and Przewlocki, [@B196]
  Social behaviour                                                                             Free interaction                            Impaired                   Rat       M, F     500            12.5           90--100          Markram et al., [@B141]
  Social behaviour                                                                             Free interaction                            Impaired                   Rat       M        600            12.5           90--120          Schneider and Przewlocki, [@B196]
  ***Stereotyped, repetitive behaviours (focal prenatal VPA exposure)***                                                                                                                                                                
  Repetitive behaviour                                                                         Opto-Varimex cage                           Enhanced                   Rat       M        600            12.5           30--50           Schneider and Przewlocki, [@B196]
  Repetitive behaviour                                                                         Opto-Varimex cage                           Enhanced                   Rat       M        600            12.5           90--120          Schneider and Przewlocki, [@B196]
  Spontan. alterations                                                                         Y-maze                                      Reduced                    Rat       M, F     500            12.5           80--90           Markram et al., [@B141]
  ***Stereotyped, repetitive behaviours (prolonged prenatal VPA exposure)***                                                                                                                                                            
  Spontan. alterations                                                                         T-maze                                      No effect                  Rat       M, F     150            7--18          70               Vorhees, [@B230]
  Spontan. alterations                                                                         T-maze                                      Reduced                    Rat       M, F     200            7--18          70               Vorhees, [@B230]
  ***Learning and memory (focal prenatal VPA exposure)***                                                                                                                                                                               
  Spatial learning                                                                             Morris water maze                           Impaired                   Mouse     M, F     600            13             20--26           Wagner et al., [@B232]
  Spatial learning                                                                             Object recognition                          No effect                  Rat       M        600            12.5           60--90           Schneider et al., 2007
  Spatial learning                                                                             Morris water maze                           No effect                  Rat       M, F     500            12.5           90--110          Markram et al., [@B141]
  Eye blink conditioning                                                                       Discriminative eye-blink conditioning       Enhanced                   Rat       M, F     600            12             26--31           Stanton et al., 2006
  Fear conditioning                                                                            Auditory fear conditioning training         No effect                  Rat       M, F     500            12.5           120--122         Markram et al., [@B141]
  Fear conditioning                                                                            Auditory fear generalization                Enhanced                   Rat       M, F     500            12.5           124              Markram et al., [@B141]
  Fear conditioning                                                                            Auditory fear memory                        Enhanced                   Rat       M, F     500            12.5           124--174         Markram et al., [@B141]
  Fear conditioning                                                                            Contextual fear memory                      Enhanced                   Rat       M, F     500            12.5           123--173         Markram et al., [@B141]
  Conditioned place aversion                                                                   Conditioned place aversion to naloxone      Impaired                   Rat       M        600            12.5           60--90           Schneider et al., 2007
  Fear extinction                                                                              Contextual fear extinction                  Impaired                   Rat       M, F     500            12.5           174--180         Markram et al., [@B141]
  Fear extinction                                                                              Tone fear extinction in same context        Impaired                   Rat       M, F     500            12.5           174--180         Markram et al., [@B141]
  Fear extinction                                                                              Tone fear extinction in different context   No effect                  Rat       M, F     500            12.5           174--180         Markram et al., [@B141]
  Reversal learning                                                                            Discriminative eye-blink reversal           Impaired                   Rat       M, F     600            12             26--31           Stanton et al., 2006
  ***Learning and memory (prolonged prenatal VPA exposure)***                                                                                                                                                                           
  Spatial learning                                                                             Cincinnati water maze                       No effect                  Rat       M, F     150            7--18          51--54; 57--58   Vorhees, [@B230]
  Spatial learning                                                                             Cincinnati water maze                       No effect                  Rat       M, F     200            7--18          51--54; 57--58   Vorhees, [@B230]
  Spatial learning                                                                             Morris water maze                           No effect                  Mouse     M, F     200            12--17         20--26           Wagner et al., [@B232]
  Spatial reversal learning                                                                    Cincinnati water maze                       No effect                  Rat       M, F     150            7--18          59--61; 64--66   Vorhees, [@B230]
  Spatial reversal learning                                                                    Cincinnati water maze                       M No effect F Impaired     Rat       M, F     200            7--18          59--61; 64--66   Vorhees, [@B230]

Results describe the VPA-treated offspring group relative to controls. Abbreviations: ED, embryonic day; EPM, elevated plus maze; F, female; M, male; N, number; PND, postnatal day; PPI, pre-pulse inhibition; VPA, valproic acid.

In summary, the data obtained on the VPA rat model proposed by Rodier et al. ([@B183]) clearly indicates a strong concordance with some of the main symptoms and pathologies of autism. For this reason, we chose this model for a multi-omics approach to study the molecular, cellular, synaptic, local circuit as well as further behavioral alterations possibly underlying autism. The following subchapters summarize the main findings.

Hyper-reactivity in neocortical microcircuits
---------------------------------------------

Since high cognitive functions are affected in autism, we examined alterations in the neocortex using the VPA rat model. The results are summarized in Table [5](#T5){ref-type="table"}. The somatosensory cortex microcircuitry of two-week old VPA-treated offspring (Rinaldi et al., [@B178]) were examined after exposure on ED12.5. Brain slices were placed on a multi-electrode array (MEA) stimulator and the stimulation current was gradually increased to examine the stimulus--response relationship of the microcircuitry. The microcircuitry reacted much stronger to the same stimulus in the VPA-treated rats with nearly twice the response of the normal microcircuit. This extreme hyper-reactivity was observed in both layer 5 and in layer 2/3 indicating that the alteration is not layer specific. Recently we found that the microcircuits of the prefrontal cortex (T. Rinaldi, and H. Makram, unpublished data) and the amygdala (Markram et al., [@B141]) are also hyper-reactive indicating that the alterations are not specific to a single neocortical region and are also found in subcortical brain regions.

###### 

**Microcircuit alterations in the VPA rat model of autism**.

  Measurement                                                                                                               Region   Effect                      Dose (mg/kg)   ED VPA admin   PND testing   Reference
  ------------------------------------------------------------------------------------------------------------------------- -------- --------------------------- -------------- -------------- ------------- -------------------------
  ***Single-neuron patch clamp***                                                                                                                                                                            
  NMDAR current influx                                                                                                      S1       Enhanced                    500            12.5           12--16        Rinaldi et al., [@B179]
  AMPAR current influx                                                                                                      S1       No effect                   500            12.5           12--16        Rinaldi et al., [@B179]
  AMPA/NMDA current influx ratio                                                                                            S1       Decreased                   500            12.5           12--16        Rinaldi et al., [@B179]
  AP evoked calcium transients                                                                                              S1       No effect                   500            12.5           12--16        Rinaldi et al., [@B179]
  ***Multi-neuron patch clamp***                                                                                                                                                                             
  Direct and disynaptic connectivity between layer 5 pyramidal neurons less than 50 μm apart                                S1       Enhanced by more than 50%   500            12.5           12--16        Rinaldi et al., [@B178]
  Direct and disynaptic connectivity between layer 5 pyramidal neurons 100--200 μm apart                                    S1       No effect                   500            12.5           12--16        Rinaldi et al., [@B178]
  Strength of direct connections between layer 5 pyramidal neurons                                                          S1       Decreased                   500            12.5           12--16        Rinaldi et al., [@B178]
  Electrical excitability of layer 2/3 and 5 neurons                                                                        S1       Decreased                   500            12.5           12--16        Rinaldi et al., [@B178]
  AP amplitude, threshold, input resistance                                                                                 S1       No effect                   500            12.5           12--16        Rinaldi et al., [@B178]
  ***Network reactivity measured with MEA***                                                                                                                                                                 
  Network reactivity to excitatory inputs in layer 2/3 and layer 5 (voltage clamp at GABA~A~ reversal potential ∼ −57 mV)   S1       Enhanced                    500            12.5           12--16        Rinaldi et al., [@B178]
  Network reactivity to inhibitory inputs in layer 2/3 and layer 5 (voltage clamp at AMPA reversal potential ∼+10 mV)       S1       Enhanced                    500            12.5           12--16        Rinaldi et al., [@B178]
  Network excitatory/inhibitory balance                                                                                     S1       No effect                   500            12.5           12--16        Rinaldi et al., [@B178]
  Network reactivity to excitatory inputs (voltage clamp at GABA~A~ reversal potential ∼−57 mV)                             LA       Enhanced                    500            12.5           12--16        Markram et al., [@B141]
  Network reactivity to inhibitory inputs (voltage clamp at AMPA reversal potential ∼+10 mV)                                LA       Decreased                   500            12.5           12--16        Markram et al., [@B141]
  Reverberant activity                                                                                                      LA       Enhanced                    500            12.5           12--16        Markram et al., [@B141]
  ***Synaptic plasticity***                                                                                                                                                                                  
  Postsynaptic LTP                                                                                                          S1       Enhanced                    500            12.5           12--16        Rinaldi et al., [@B179]
  Postsynaptic LTP                                                                                                          LA       Enhanced                    500            12.5           12--16        Markram et al., [@B141]

Results describe the VPA-treated offspring group relative to controls. All studies were performed on male rats. Abbreviations: AP, action potential; ED, embryonic day; LA, lateral nucleus of the amygdala; LTP, long-term potential; M, male; S1, primary somatosensory cortex; VPA, valproic acid.

Enhanced reactivity of microcircuits could be caused by larger synaptic currents, hyper-excitable neurons due to changes in active conductance, lack of proper inhibitory control, alterations in neuron numbers and morphology or by excessive recurrent circuitry. Excitatory synaptic responses studied in paired recordings revealed that the AMPA-mediated synaptic responses of connections between neurons were weaker rather than stronger in the VPA-treated rat offspring, which could not explain the hyper-reactivity. Anatomical reconstructions revealed that less synapses are deployed in each synaptic connection, which could account for these weaker synaptic connections.

Passive and active properties of the excitatory pyramidal neurons were examined. The pyramidal neurons required much more current to drive their voltage to spiking threshold and the number of spikes generated for a series of current injections was much lower than in controls. There were no differences in the passive properties indicating that it is the active excitability of pyramidal neurons that is depressed in this animal model of autism. This hypo-excitability of pyramidal neurons can clearly not cause hyper-reactivity to stimulation, and may in fact be an attempt to counter the hyper-reactivity as a compensatory mechanism.

The inhibitory component of the excessive response of the microcircuitry was also greater as compared to control rats. The balance between excitation and inhibition was not affected indicating that inhibition is increased proportionately to excitation. The increased delivery of inhibition is most likely due to matching recruitment of inhibitory neurons by the stronger excitatory response in the treated rats. Hyper-reactivity of the microcircuitry also cannot be caused by excessive inhibition in the neocortical microcircuitry.

Morphological examination of 3D reconstructions of biocytin stained pyramidal neurons did not show any significant differences in the extent of axonal or dendritic arbors, in the spine or bouton densities, and in the size of pyramidal neuron somata. There was also no change in the number of pyramidal neurons. Hyper-reactivity of the neocortical microcircuitry is therefore not caused by larger or more elaborate neurons, more excitable neurons, an increase in neuron numbers, more powerful synapses between neurons, nor by a loss of inhibition. Indeed, changes in these parameters seem to act in the opposite direction, perhaps part of a compensatory strategy.

Hyper-connectivity in neocortical microcircuits
-----------------------------------------------

We examined the number of direct connections established between pyramidal neurons and found an increase of more than 50% in the number of neurons connected in VPA-treated offspring (Rinaldi et al., [@B178]). This hyper-connectivity was only found for very close neighboring neurons confined within the typical dimensions of a neocortical minicolumn (∼50 μm somatic distance, and not for pairs of pyramidal neurons 100--200 μm apart). The probability of activating inhibitory interneurons by studying a disynaptic inhibitory connection between pyramidal neurons (Silberberg and Markram, [@B212]) also revealed a significant increase of more than 50%. This indicates that activating pyramidal neurons can indeed recruit proportionately more interneurons due to hyper-connectivity which extends beyond pyramidal neurons. Hyper-connectivity in microcircuits can lead to exaggerated recruitment of neurons when presented with a stimulus and could therefore account for the hyper-reactivity found in these local circuits. The results are summarized in Table [5](#T5){ref-type="table"}.

An intriguing aspect of this hyper-connectivity is the finding that pyramidal neurons target more neurons even at the expense of deploying less synapses per connection. This form of hyper-connectivity is, therefore, not a general hypertrophy of synapse formation, but rather a hypertrophy of connectivity between neurons. We, therefore, propose that a novel molecular mechanism involved in "target dominance" is enhanced in the VPA-treated neocortex and this molecular syndrome triggered by VPA exposure causes hyper-reactivity.

Hyper-plasticity in neocortical microcircuits
---------------------------------------------

Since memory processes are also altered in autism, we examined whether synaptic plasticity is affected in the VPA-treated neocortex (Rinaldi et al., [@B179]). The results are summarized in Table [5](#T5){ref-type="table"}. Synaptic responses recorded in pyramidal neurons following a Hebbian pairing stimulation protocol caused more than a two-fold increase in the subsequent synaptic responses (i.e., enhanced long term potentiation). The results were also found for both layer 2/3 and in layer 5 pyramidal neurons and a closer examination revealed that the boosted plasticity was a postsynaptic form of plasticity. The presynaptic form of plasticity that is normally observed between these neurons was normal in the VPA treated slices. These results indicate that glutamatergic synapses are hyper-plastic in this animal model of autism.

Hyper-expression of NMDA receptors in the neocortex
---------------------------------------------------

To better understand the molecular syndrome underlying the hyper-plasticity, we tested for protein expression alterations (Rinaldi et al., [@B179]). The results are summarized in Table [3](#T3){ref-type="table"}. We found that the AMPA receptor subunits GluR1, GluR2, and GluR3 and the obligatory subunit of the NMDA receptor, NR1, were unaltered in the VPA-treated neocortex. However, the expression level of the NMDA receptor subunits NR2A and NR2B were massively over-expressed (more than 100%). We did not find evidence that this enhanced NMDA receptor subunit levels rendered neurons more vulnerable to neurotoxicity.

We also found a large increase in the level of CaMKII protein expression (more than 60%), which is a key signaling enzyme associated with NMDA receptor-mediated synaptic plasticity. In contrast, the expression level of extracellular signal-regulated kinase (ERK) and cAMP response element binding protein (CREB), some phosphorylated forms of signaling proteins (pCREB-S133, pCaMKII-T286/287, GluR1-S831, pGluR1-S845, pNR1-S896, pNR1-S897, pNR2B-S1303), as well as the main metabotropic glutamate receptor subunits (mGluR1, mGluR5, mGluR4, mGluR6/7) and the kainite receptor subunits (GluR6/7), were unaffected. This indicated that NMDA receptor subunit levels are excessively expressed and that this is a highly selective abnormality within the glutamatergic system of this animal model of autism.

We performed multi-neuron patch-clamp experiments on slices of the somatosensory cortex to directly examine the synaptic currents mediated by AMPA and NMDA receptors between pairs of pyramidal neurons. Indeed, we found that much more charge entered the postsynaptic cells through the NMDA receptors consistent with the increased expression of the NMDA receptors. The decay-time courses of the NMDA receptor mediated currents were, however, unaffected suggesting that the proportions of subunits used in the assembly of NMDA receptors were not affected. We do not however know whether the normal developmental switches in sub-units are affected at a later stage.

Hyper-fear memories
-------------------

Kanners\' original case studies (1943) suggested that some of the autistic children he observed exhibited abnormal anxiety levels and phobias. More recent studies have also suggested abnormally high anxiety levels and phobias in children with ASD (Evans et al., [@B90]; Gillott et al., [@B99]; Muris et al., [@B157]) and their relatives (Micali et al., [@B147]). We found that VPA-treated offspring exhibited greatly amplified conditioned cued and contextual fear memories when tested up to 3 months after conditioning. Fear memories were not only amplified, but also more generalized to other stimulus configurations (Markram et al., [@B141]) (Table [4](#T4){ref-type="table"}). These data indicated that VPA-treated animals are not only overtly anxious, but also acquire fear memories in an exaggerated manner. It is, however, not clear if enhanced fears are common across the autistic spectrum since two recent studies indicate that some high functioning autists, in particular patients diagnosed with Asperger disorder, do not seem to display abnormal conditioned fear (Bernier et al., [@B38]; Gaigg and Bowler, [@B94]).

Impaired fear extinction
------------------------

Extinction is usually defined as a learning process in which a new (probably inhibitory) association is built, namely that the conditioned stimulus no longer predicts danger (Quirk, [@B171]; Rescorla, [@B176]). Extinction training has been shown to involve a network of interactive brain regions, with connections between the medial prefrontal cortex and the amygdala playing a prominent role (Barad, [@B28]; Quirk and Beer, [@B172]; Sotres-Bayon et al., [@B214]; Sotres-Bayon et al., [@B215]). Autistic children are known to have impairments in extinction learning and to display strong perseveration tendencies (Coldren and Halloran, [@B63]; Mullins and Rincover, [@B156]; Sears et al., [@B206]), but it was not known whether this applies to the fear domain as well. We found that once fear memories were acquired by VPA-treated rat offspring, they were exceedingly more resistant to extinction than in control animals (Markram et al., [@B141]) (Table [4](#T4){ref-type="table"}).

Hyper-reactivity in the amygdala microcircuitry
-----------------------------------------------

The amygdala is a crucial brain structure mediating generalized anxiety and fear conditioning (Davis and Whalen, [@B82]; LeDoux, [@B137]). We, therefore, attempted to understand the microcircuit changes in the amygdala that could underlie the increased fear memories, over-generalization of conditioned fear and resistance to fear extinction which we observed in the VPA-treated offspring (Markram et al., [@B141]). We found that the lateral amygdala microcircuit was also extremely hyper-reactive when stimulated with progressively stronger electrical stimulations using the MEA stimulator (Table [5](#T5){ref-type="table"}). The amygdala responded differently from the neocortex in that stimulation easily produced prolonged episodes of up-state-like bursts. The number, frequency and duration of these evoked up-states were all greatly enhanced in slices from VPA-treated animals. When we isolated the inhibition, we found that, unlike in the neocortex, inhibition was greatly reduced. We have not yet been able to obtain sufficient data to determine whether the excitatory cells of the amygdala are hyper-connected as in the neocortex, but the cellular and synaptic alterations are such that they also result in hyper-reactivity.

Hyper-plasticity in the amygdala microcircuitry
-----------------------------------------------

We examined whether synaptic plasticity was affected in the amygdala and found an equally significant enhancement of long-term potentiation (Markram et al., [@B141]) (Table [5](#T5){ref-type="table"}) as in the neocortex. Interestingly amygdala disinhibition induced either by GABAergic blockade (Isoardi et al., [@B123]), genetic knockout of the GABAB(1a)-receptor subtype (Shaban et al., [@B207]), benzodiazepine withdrawal (Isoardi et al., [@B123]), dopamine receptor activation (Bissiere et al., [@B42]), or stress (Rodriguez Manzanares et al., [@B184]), can result in amygdaloid hyper-excitability (Isoardi et al., [@B123]; Rodriguez Manzanares et al., [@B184]) and facilitate LTP induction (Bissiere et al., [@B42]; Rodriguez Manzanares et al., [@B184]; Shaban et al., [@B207]), which has been associated not only with enhanced fear memories (Isoardi et al., [@B123]; Rodriguez Manzanares et al., [@B184]), but also with over-generalization of conditioned fear to neutral stimuli (Shaban et al., [@B207]).

Autism as an Intense World Syndrome
===================================

Autism is a polygenetically predisposed neurodevelopmental disorder that is most likely triggered by an epigenetic attack from multiple potential sources to set in motion a genetic and molecular cascade -- a molecular syndrome - that unfolds a spectrum of disorders. All forms of autism have a vague commonality and the question is whether there is a common molecular syndrome producing common neurophysiological, cognitive, and behavioral pathologies. We propose here a potentially unifying hypothesis of autism in which a common molecular syndrome causes excessive neuronal information processing and storage in the microcircuits of the brain. Such excessive information handling is proposed to produce *hyper-perception, hyper-attention, and hyper-memory*, which could become the fundamental cognitive handicap in all cases of autism. We further propose that the core molecular syndrome that causes excessive information processing and storage does so by causing *hyper-reactivity and hyper-plasticity* of the brains\' microcircuits. In the neocortex, this core pathology is caused by *hyper-connecting neighbouring neurons to produce excessive excitation and by hyper-expressing NMDA receptors to produce excessive plasticity.* On the other hand, in the amygdala, the hyper-reactivity seems to additionally involve diminished inhibitory synaptic transmission. Hyper-reactivity may therefore be caused additionally by reducing inhibition in those brain regions with high numbers of inhibitory neurons. Indeed, a reduction in the inhibitory Purkinje cells in the cerebellum is well known (Bailey et al., [@B26]; Kemper and Bauman, [@B125]; Ritvo et al., [@B181]; Rodier et al., [@B183]). The full spectrum of autism may be explained by the varying degrees of expression of the molecular syndrome that drives hyper-reactivity and hyper-plasticity in different brain regions, depending on the precise moment that the developing brain was exposed to a triggering insult, the type of insult, and the presence of any predisposing genes.

This core hyper-functioning pathology is proposed to cause the spectrum of autistic symptoms by rendering local neural circuits hyper-sensitive to novel and past stimulation, and once activated, these microcircuits could become autonomous, difficult to control and coordinate with the activity in other microcircuits. Hyper-reactivity and hyper-plasticity are therefore proposed to cause exaggerated perception to fragments of a sensory world that are normally holistically correlated and multimodal, and furthermore to cause hyper-focusing on fragment of the sensory world with exaggerated and persistent attention. Such hyper-attention could become difficult to shift to new stimuli due to the difficulty for top-down mechanisms to coordinate the overly autonomous microcircuits. The hyper-plasticity component may also drive exaggerated memories to amplify further hyper-attention towards the same stimulus and drive over-generalization of attention to all related forms of the stimulus. The positive consequences are exceptional capabilities for specific tasks while the negative consequences are a rapid lock down of behavioral routines to a minute fraction of possibilities, which are then repeated excessively.

The intense world that the autistic person faces could also easily become aversive if the amygdala and related emotional areas are affected with hyper-reactivity and hyper-plasticity. The lack of social interaction in autism may therefore not be because of deficits in the ability to process social and emotional cues as previously thought, but because a subset of cues are overly intense, compulsively attended to, excessively processed and remembered with frightening clarity and intensity. Autistic people may, therefore, neither at all be mind-blind nor lack empathy for others, but be hyper-aware of selected fragments of the mind, which may be so intense that they avoid eye contact, withdraw from social interactions and stop communicating. In such a scenario, the world may become painfully intense for autistics and we, therefore, propose autism as an *Intense World Syndrome*. We now review some of the key findings in past autism research and provide a possible alternative interpretation of the results in the light of the hypothesized syndrome.

Core Pathologies in Autism in the Light of the Intense World Syndrome
=====================================================================

The neurobiological research on autism is about 35 years old with a large number of findings many of which are controversial. Amongst the most consistent findings are the paucity of Purkinje cells in the cerebellar hemispheres (Palmen et al., [@B162]), increased platelet serotonin levels (Lam et al., [@B133]) and accelerated brain growth in early infancy (Courchesne et al., [@B73]). Recent advances made with functional neuroimaging techniques have contributed greatly to the understanding of the autistic brain.

Accelerated brain growth
------------------------

The human brain continues to develop considerably throughout the first years of life. In the normal brain this development follows a specific hierarchical scheme where basic sensory areas mediating perceptual function, mature earlier than higher order association areas such as the frontal cortex. Such progressive neurodevelopment underlies the later development of refined skills and higher cognitive, emotional, social, and communication functions.

One of the most striking and reliable observations in the autistic brain is its abnormal development. Newborn autistic infants usually exhibit a normal (Gillberg and de Souza, [@B98]; Lainhart et al., [@B132]; Stevenson et al., [@B220]) or even slightly smaller than normal brain size (Courchesne et al., [@B73]). However, within the first year of life there is an accelerated growth (Dementieva et al., [@B83]), such that by the age of 2--3 years the overall volume is about 10% greater than normal (Courchesne et al., [@B76]; Sparks et al., [@B216]). The accelerated growth takes place in a more or less reverse hierarchical order with the frontal and temporal lobes, the limbic system and the cerebellum leading the development (Courchesne, [@B71]). In the neocortex, for example, the white matter increase is most pronounced in the frontal, followed by the temporal and parietal lobes, whereas occipital lobes remain normal (Carper et al., [@B50]). In 2--3 years old autistic kids, gray matter is increased most in the frontal followed by the temporal lobes (Carper et al., [@B50]). In the limbic system the amygdala and hippocampus are enlarged in children ranging from 3 to 13 years of age (Schumann et al., [@B205]; Sparks et al., [@B216]), while in older subjects, the amygdala volume seems comparable to normal people or even smaller (Courchesne et al., [@B72]; Dziobek et al., [@B87]; Haznedar et al., [@B109]; Nowell et al., [@B160]; Palmen et al., [@B163]; Schumann et al., [@B205]), but the results are not always consistent (Abell et al., [@B1]; Howard et al., [@B119]). The abnormally accelerated growth early in childhood is followed by an abnormally slow or arrested growth in later childhood. In other words, the autistic brain outruns the normal brain within the first 4 years of life, reaching mature levels in higher brain regions too soon and then ceases to develop further. Thus, throughout childhood the normal rate of growth declines and the normal brain catches up until the size of the autistic brain is only 1--2% above normal in adolescence (Redcay and Courchesne, [@B175]).

The excessive growth could be due to neuronal, synaptic, and/or connection hypertrophy. The question is whether there is a link between the regions that grow too fast and their normal local circuit properties that could explain the reverse development of some brain regions. The level of reactivity of local circuits is finely tuned to allow all brain regions to act in an orchestrated manner. This level reflects a balance between the number of synapses each neuron uses to contact neighbors and the number of neighbours that can be contacted as well as the manner in which inhibition counters the excitation of any neuron. This balance determines the impact of each neuron on the microcircuit, which is normally very small, but varies for different brain regions. For example, the higher neocortical regions such as the prefrontal cortex displays higher local connectivity in the normal case (Wang et al., [@B234]) which makes the prefrontal cortex normally more reactive than sensory areas allowing this region to more easily display sustained states of activity (Goldman-Rakic, [@B100]; Miller et al., [@B148]). The prefrontal cortex is also hyper-reactive in the VPA animal model (T. Rinaldi and H. Markram, unpublished data). It may, therefore, be possible that while the hierarchy of brain region development is normally inverse to how reactive the local circuits are set to become, this negative correlation switches to a positive one in the autistic brain upsetting the normal sequence of first developing rudimentary sensory and motor processing abilities. Since hyper-reactivity may be caused in a number of ways (hyper-connectivity, hyper-excitable excitatory neurons, hypo-excitable inhibitory neurons, upsetting the excitation-inhibitory balance, lowering long-range control pathways into microcircuits, etc.), each region may switch their developmental sequences differently depending on the predominant mechanisms setting the reactivity level. Furthermore, while the core outcome of the molecular syndrome of autism is proposed to cause hyper-reactivity and hyper-plasticity at the microcircuit level, the syndrome may also act at the system level to render the whole brain hyper-reactive and hyper-plastic and system level factors may also determine which brain areas develop more rapidly than others in autism.

Cellular alterations
--------------------

Postmortem neuropathology on autopsied autistic brains (Bailey et al., [@B26]; Coleman et al., [@B64]; Kemper and Bauman, [@B125]; Rodier et al., [@B183]; Williams et al., [@B239]) revealed alterations in neuronal anatomy within frontal (Bailey et al., [@B26]; Kemper and Bauman, [@B125]), temporal (Bailey et al., [@B26]), parietal (Bailey et al., [@B26]), limbic (Bailey et al., [@B26]; Kemper and Bauman, [@B125]; Raymond et al., [@B174]) and cerebellar (Bailey et al., [@B26]; Kemper and Bauman, [@B125]; Ritvo et al., [@B181]; Rodier et al., [@B183]) regions. Bailey et al. ([@B26]) reported irregular laminar patterns in the frontal lobe, ectopic neurons in the white matter, thickened areas in the parietal, temporal, frontal, and cingulate lobes, and increased neuronal density and subplial gliosis in the right cerebral hemisphere in four out of six autistic subjects with low IQs. Kemper and Bauman ([@B125]) investigated the brains of nine autistic subjects. In eight out of nine subjects they found abnormally small neurons and increased cell packing in the anterior cingulated gyrus, amygdala, hippocampus, subiculum, enthorinal cortex, mamillary body, and medial septum. Higher numbers of smaller neurons in the neocortex of humans may be part of the strategy of the autistic molecular syndrome to increase the number of target neurons for neurons to contact. Neurons in the CA1 and CA4 subregion of the hippocampus exhibited reduced complexity and less extensive dendritic arbors (Raymond et al., [@B174]). Interestingly, local connectivity in these hippocampal regions is normally extremely low perhaps consistent with the hypothesized positive correlation between local connectivity and regional brain development in autism.

The cerebellum is a powerful inhibitory brain region and one of the most consistent findings in autism is a reduced number of its\' principal inhibitory neurons -- the Purkinje cells (Courchesne et al., [@B75]; Kemper and Bauman, [@B125]; Rodier et al., [@B183]; Ritvo et al., [@B181]). These changes in the cerebellum, may be part of the manifestations of the molecular syndrome driving hyper-reactivity at the level of brain regions -- a systems wide manifestation.

Modern stereological counts of neuron number mostly confirm the above studies and reveal an excess number of neurons in the cerebrum and a decreased amount of neurons in the cerebellum (Courchesne et al., [@B75]). However, contrary to earlier studies, modern stereological counts on the autistic amygdala revealed fewer neurons overall and in particular in the lateral nucleus (Schumann and Amaral, [@B204]).

Further evidence for altered neuronal anatomy and circuitry stems from recent studies on minicolumnar arrangements in the neocortex (Casanova et al., [@B51]). The minicolumn is thought to be the smallest computational circuit in the brain (Mountcastle, [@B152]). It consists of a core line of vertically ascending pyramidal and inhibitory neurons, their connections and input/output axons. A minicolumn is 30--60 μm in diameter and contains around 120 neurons and is relatively consistent in size in different species and neocortical regions (with some exceptions). Minicolumns in nine autistic brains were abnormally narrow, both in the column core as well as in the neurophil, in the frontal and temporal lobes (Casanova et al., [@B51]). This suggests that the autistic brain exhibits an increased number of minicolumns, thus more processing units (Casanova et al., [@B51]). One should however ask, why minicolumns are not just larger to accommodate the excess number of neurons? Hyper-connectivity found in the animal model is restricted to the minicolumnar dimensions, which may not only render these minicolumns more tightly coupled internally, but may also facilitate the parcellation of neurons into more minicolumns.

Hyper-connectivity leading to hyper-reactivity could render minicolumns more independent from surrounding minicolumns and autonomous once activated, but more difficult to collectively coordinate activity across multiple minicolumns and in concert with the rest of the brain. The neurophil space around the mincolumn core in humans is also reduced (Casanova et al., [@B51]), which contains important types of interneurons and such a deficit in inhibition could further add to the autonomy of the minicolumns caused by the molecular syndrome driving hyper-reactivity.

Hyper-seretonemia
-----------------

Many neurotransmitter systems have been studied in autism including serotonin (5-HT), dopamine, norepinephrine, acetylcholine, glutamate, gamma-aminobutyric acid, endogenous opiods, oxytocin, and cortisol (reviewed in Lam et al., [@B133]). The most studied neurotransmitter is 5-HT as it proves to be the best bio-chemical marker of autism so far. The behavioral effects of 5-HT are complex, as it regulates mood, eating, body temperature, arousal, and modulates pain sensitivity, sexual behavior, and hormone release. Serotonin blood levels are highly elevated in a significant number of autistic children (Anderson et al., [@B18]; Betancur et al., [@B39]; Cook et al., [@B68]; Schain and Freedman, [@B194]). Higher rates of autism also occur in children exposed *in utero* to drugs known to increase 5-HT levels such as cocaine (Kramer et al., [@B131]). Direct *in vivo* measurements using positron emission tomography (PET) demonstrated asymmetries of 5-HT synthesis in the frontal cortex, thalamus and cerebellum in autistic boys, but not in autistic girls or in normal siblings (Chugani, [@B58]; Chugani et al., [@B61]). Also, while 5-HT synthesis is usually high in young children and then gradually declines, the levels are persistently high in autistic children (Chugani, [@B58]; Chugani et al., [@B59]; Chugani et al., [@B60]). A number of studies have attempted to elucidate the causes of mean level elevation seen for platelet 5-HT in autism, but metabolism, catabolism and transport mechanisms for 5-HT do not seem to be affected in autism (Anderson et al., [@B16]; Anderson et al., [@B17]; Cook et al., [@B67]), which may suggest that the elevated 5-HT levels are more secondary in the disorder to excessive stimulation of synthesis and release.

The main problem with the 5-HT theory of autism as a primary cause of autism is that treatments which further increase 5-HT levels seem to improve some symptoms of autism, such as obsessionality and social relatedness (McBride et al., [@B143]), while depletion of tryptophan, a serotonin precursor, seems to exacerbate autistic symptoms such as flapping, banging and self-hitting, rocking and increase anxiety (McDougle et al., [@B144]).

5-HT is not only a neurotransmitter, but also regulates the development of target brain areas, such as the neocortex, hippocampus, and cerebellum. Depletion of serotonin results in a significant delay in maturation of the somatosensory cortex (Bennett-Clarke et al., [@B37]). In contrast, excessive serotonin during early development results in hyper-innervation and expansion of cortical architecture (Cases et al., [@B52]). Embryonic exposure to VPA in the rat was also found to dramatically increase the serotonin levels in the blood as well as the frontal cortex, hippocampus, and cerebellum (Narita et al., [@B159]; Tsujino et al., [@B229]). 5-HT excess may therefore participate in the molecular syndrome that drives the altered developmental patterns and perhaps also plays a role in driving hyper-reactivity and hyper-plasticity early in development.

Altered brain activity
----------------------

Advances made with functional neuroimaging techniques have contributed greatly to the understanding of the autistic brain. The most pronounced being the reduced activity in higher order association cortices, the frontal and temporal regions, as well as in the cerebellum while activity in lower order sensory regions are normal or even slightly increased (Di Martino and Castellanos, [@B84]). These findings have been interpreted to reflect a lack of functionality, impaired long-range connections, and reduced top--down control of primary areas

Courchesne et al. ([@B75]) summarized the functional neuroimaging data which indicates reduced activation of the frontal cortex in a theory of mind task (Castelli et al., [@B53]), in response to socially familiar faces (Pierce et al., [@B167]), in face recognition (Hubl et al., [@B120]), in a working memory task (Luna et al., [@B139]), in an embedded figures task (Ring et al., [@B180]), in visual spatial attention tasks (Belmonte and Yurgelun-Todd, [@B35]) and during sentence comprehension (Just et al., [@B124]; Muller et al., [@B154]). Additionally, EEG studies consistently found reduced or absent electrical responses from the frontal cortex in several auditory and visual attention and orienting tasks (Ciesielski et al., [@B62]; Courchesne et al., [@B74]; Townsend et al., [@B228]). Temporal lobe activation was also found to be reduced during processing of vocal sounds (Gervais et al., [@B95]), speech sounds (Boddaert et al., [@B44]; Muller et al., [@B155]), face recognition (Pierce et al., [@B168]; Pierce et al., [@B167]; Schultz et al., [@B202]), and theory of mind tasks (Castelli et al., [@B53]). Impaired amygdala activation was reported in tasks of face perception and evaluation of facial expressions (Baron-Cohen et al., [@B32]; Critchley et al., [@B78]; Pierce et al., [@B168]). In striking contrast to the hypo-activation of the frontal and temporal lobes is the normal or even hyper-activation of the occipital lobe in response to visual stimulation (Belmonte and Yurgelun-Todd, [@B35]; Hadjikhani et al., [@B102]; Hubl et al., [@B120]; Ring et al., [@B180]).

These imaging results seem to be consistent with cognitive theories (see following chapters) built around autistic people\'s apparent inability to empathize with other peoples feelings and thoughts (Frith and Happe, [@B93]), deficits in executive function (Russell, [@B188]), deficits in holistic (or Gestalt processing) with a simultaneous preference for details (Frith, [@B92]; Happe and Frith, [@B106]), and deficits in face perception and evaluation of social cues from facial expressions (Schultz, [@B200]).

It is, however, not trivial to interpret functional brain imaging results in the autistic brain since highly reactive and autonomous microcircuits may be difficult to activate in a coherent manner with normal stimuli and tasks. They may, therefore, be hypo-active, but hyper-reactive to a highly selected set of stimuli. Indeed, cerebellar responses can be reduced, normal and increased depending on the task. Reduced activation was reported in attention tasks (Allen and Courchesne, [@B11]), speech recognition and generation (Muller et al., [@B154]; Muller et al., [@B155]) and judgement of facial expressions and normal to increased activation was observed during motor tasks (Allen and Courchesne, [@B11]; Allen et al., [@B12]; Muller et al., [@B153]). Normal stimulus paradigms may, therefore, not be optimal for the stimulation of the autistic brain and reduced activity for normal stimulation may not be indicative of lower functionality. There is also the additional problem of potentially higher baseline levels of activation in the autistic brain, which may render the difference responses apparently lower.

Reduced functional connectivity
-------------------------------

Functional connectivity studies have suggested reduced connectivity between occipital and frontal or temporal lobes (Castelli et al., [@B53]), superior temporal to inferior frontal lobes (Just et al., [@B124]), and parietal to frontal lobes (Horwitz et al., [@B118]). This has been interpreted as support for the reduced long-distance connectivity hypothesis of autism. While reduced long-range connectivity may go hand in hand with enhanced local connectivity, the later alone may also be sufficient to produce results that could be interpreted as reduced functional long-range connectivity since the microcircuits would be more difficult to coordinate and engage when they can easily become autonomously active.

Overall, functional imaging studies seem to suggest that higher order brain areas are not fully activated, are disconnected from lower order sensory areas and that lower order sensory areas may even be hyper-activated. We hypothesise that it is easier to apply the appropriate stimulation to observe the hyper-reactivity in lower areas while much more complex stimulation patterns would be required to observe the hyper-reactivity in higher brain areas. Nevertheless, the cognitive consequences are perhaps similar in that information from one area might not be easily integrated with information from another area, thus leaving the autistic person in a world of "bits and pieces" that may seem isolated and feel chaotic and confusing.

Theories of Autism Re-Interpreted in the Light of the Intense World Syndrome
============================================================================

Weak central coherence theory
-----------------------------

Autistic individuals do display abnormally weak central coherence required to integrate sensory information in a holistic (Gestalt) manner (Frith, [@B92]; Happe and Frith, [@B106]) and display "piece meal perception" which seems to arise because they are easily trapped into processing spurious stimuli with extreme detail. These assumptions are summarized in the "weak central coherence theory of autism" (Frith, [@B92]; Happe and Frith, [@B106]) and have been supported by experimental tasks, in which weak central coherence would be expected to have a task advantage over integrative, Gestalt perception or tasks in which integrative information processing would give an advantage over detailistic feature processing. For example, autistic subjects tend to perform better than controls on the Wechsler Block Design task, which is due to a greater ability to segment the whole design into its component parts (Shah and Frith, [@B209]) and in the Embedded Figures Test (Shah and Frith, [@B208]). In contrast, in a homograph disambiguation task which specifically requires the processing of information in context, autistic individuals fail to use preceding sentence context to determine the correct pronunciation of the homographs (Happe and Frith, [@B105]).

Support for piece-meal perception comes also from fMRI studies on face perception (Pierce et al., [@B168]). In normal subjects, faces consistently activate the fusiform face area in the fusiform gyrus while in autistic subjects, these regions exhibit abnormally weak or no activation at all (Schultz et al., [@B201]). Interestingly, in autistic subjects the activation pattern evoked by faces is rather distributed over several cortical regions (e.g., frontal, primary visual, cerebellum, etc.) and is different from subject to subject, suggesting each autistic individual activates different distributed neural systems (Pierce et al., [@B168]), which may be due to different degrees of hyper-reactivity in affected regions. We propose that piece meal perception is primarily due to hyper-functionality of local microcircuits.

Executive function theory
-------------------------

Data supporting hypo-functionality of the frontal lobes and loss of top--down control has also supported the "executive function theory of autism" (Russell, [@B188]) which proposes that the strong repetitive routines and preference for sameness in autism is due to impairments in executive functions. The term "executive functions" encompass many kinds of mental operations which enable an individual to disengage from the immediate context in order to guide behavior based on mental models or future goals, a function which is highly dependent on the integrity of the prefrontal lobes. These interpretations are further supported by findings that patients with frontal lobe lesions also exhibit symptoms of perseveration and the inability to shift attention and autistic subjects do perform badly on tests of executive function, such as the classic Wisconsin card sorting test (Ozonoff et al., [@B161]; Rumsey and Hamburger, [@B187]; Sandson and Albert, [@B193]) or the Tower of Hanoi planning task (Ozonoff et al., [@B161]).

We propose that the frontal cortices become functionally impaired because of the hyper-functionality of the microcircuits, which excessively process and remember fragments of information, and further amplify the hyper-attention to the same details. The theory predicts that these regions are not hypo-functional and that presentation of stimuli or tasks that the autistic child prefers will produce elevated responses above controls. Furthermore, impairments of higher cognitive functions observed in autism (Minshew et al., [@B149]), which are currently either attributed to a hypo-functioning of higher order brain regions or disconnection phenomena, could also be due to a failure to control the autonomous hyper-functional microcircuits. Hyper-functionality is also consistent with the hypertrophy of these regions during development.

Mind blindness and emphasizing deficit theory
---------------------------------------------

Autistic people are thought to be severely impaired in empathising with other people and "reading their mind", which is captured in the "theory of mind" or "mind-blindness theory" of autism (Baron-Cohen et al., [@B29]; Frith and Happe, [@B93]). The theory involves two elements: (1) the ability to attribute mental states to oneself and others, to be able to distinguish between oneself and others and realize that others have independent minds and may pursue different goals from oneself; (2) the ability to express an appropriate emotional reaction to the other person\'s mental state, thus to be able to empathize with the others\' mind. The proposed deficits in reading other people\'s feelings and thoughts and the lack in emphasizing with other people has been commonly used to explain the impairments in social interactions and communication as well as inappropriate responses in social encounters and a few functional imaging studies suggest that these deficits may be mediated by a hypo-active amygdala (Baron-Cohen et al., [@B32]; Critchley et al., [@B78]; Pierce et al., [@B168]). Indeed the amygdala plays a pivotal role in modulating and regulating emotional responses (Adolphs, [@B2]; Davis and Whalen, [@B82]; LeDoux, [@B137]; McGaugh, [@B145]; Zald, [@B241]) and a malfunctioning in this particular brain region has been proposed to underlie the social deficits in autism (Amaral et al., [@B15]; Bachevalier and Loveland, [@B24]; Baron-Cohen et al., [@B31]; Schultz, [@B200]; Sweeten et al., [@B223]). Indeed we and other groups found social impairments after embryonic exposure to VPA in rats as well (Schneider et al., 2005, Markram et al., [@B141]). However, because we were able to use invasive techniques we observed a hyper-reactive and hyper-plastic amygdala, as expressed in terms of hyper-reactivity to electrical stimulation as well as amplified fear memories (Markram et al., [@B141]). Hyper-reactivity and hyper-plasticity were also found in the primary somatosensory cortex (Rinaldi et al., [@B178]).

We, therefore, propose that the autistic person may perceive its surroundings not only as overwhelming intense due to hyper-reactivity of primary sensory areas, but also as aversive and highly stressful due to a hyper-reactive amygdala, which also makes quick and powerful fear associations with usually neutral stimuli. The autistic person may well try to cope with the intense and aversive world by avoidance. Thus, impaired social interactions and withdrawal may not be the result of a lack of compassion, incapability to put oneself into some else\'s position or lack of emotionality, but quite to the contrary a result of an intensely if not painfully aversively perceived environment.

Since enhanced emotionality (along with enhanced perception) is a crucial point in the suggested *Intense World Syndrome* of autism we dedicate a separate chapter to the amygdala theory of autism below.

The Amygdala Theory of Autism
=============================

The amygdala has many functional roles such as detecting and interpreting signs of emotional and social significance in the environment, modulating memory storage across multiple brain sites, establishing fear memories, anxiety and the regulation of autonomic and hormonal responses (reviewed in Adolphs, [@B2]; Davis and Whalen, [@B82]; LeDoux, [@B137]; McGaugh, [@B145]; Zald, [@B241]). Dysfunction of the amygdala has been related to disorders of fear processing, anxiety, and social behaviors (reviewed in Blair et al., [@B43]; Cottraux, [@B70]; Damsa et al., [@B80]; Hajek et al., [@B103]; Shayegan and Stahl, [@B211]). The particular interest in the amygdala in autism research stems from the role it plays in the processing and interpretation of socio-emotional cues and the influence on social behaviors. The amygdala theory of autism postulates that a dysfunction in this particular brain region underlies the cardinal disturbances observed in autism, that is the difficulty in relating to others and incapability to from appropriate social interactions (Amaral et al., [@B15]; Bachevalier and Loveland, [@B24]; Baron-Cohen et al., [@B31]; Schultz, [@B200]; Sweeten et al., [@B223]). Support was provided from cellular and structural lines of investigation, which showed cellular alterations in the amygdala of autistic brains (Bauman and Kemper, [@B33]; Kemper and Bauman, [@B125]; Schumann and Amaral, [@B204]) as well as abnormal structural amygdaloid development in autism (Schumann et al., [@B205]; Sparks et al., [@B216]). We contrast the current version of the amygdala theory of autism, which implies a hypo-functioning of the amygdala, with our own version, which explicitly postulates a hyper-reactive and hyper-plastic amygdala in autism.

The "hypo-functioning" amygdala theory of autism
------------------------------------------------

The current version of the amygdala theory of autism implies a hypo-functioning of the amygdala. This is a rather implicit assumption, born mostly by the methodologies used. Amygdala lesions in non-human primates, parallels between amygdala-damaged human patients and autistic patients, as well as a few neuroimaging studies have led to this "hypo-active" amygdala theory of autism (Amaral et al., [@B15]; Bachevalier and Loveland, [@B24]; Baron-Cohen et al., [@B31]; Schultz, [@B200]; Sweeten et al., [@B223]).

### Support from lesions in non-human primates

Amygdala lesions in monkeys were the first, and for a long time the only animal model of autism available, and was based on observations that amygdala damage may lead to severe disturbances in social behavior (Bachevalier, [@B23]). The famous Kluver-Bucy syndrome is -- among other symptoms -- characterized by psychic blindness and emotional alterations, including changes or absence of anger and fear, lack of social behavior, and abnormal sexual behaviors and can be caused by bilateral damage to the amygdala (Aggleton and Passingham, [@B10]; Kluver and Bucy, [@B129]; Rosvold et al., [@B185]; Schreiner and Kling, [@B199]; Weiskrantz, [@B236]; Zola-Morgan et al., [@B242]) or the inferior temporal cortex (Horel et al., [@B117]). The cumulated results of a manifold of studies in monkeys indicated that amygdala lesions disrupt social hierarchies, species-specific social behaviors and lead to social isolation and passivity in social encounters (Bachevalier, [@B23]; Kling and Brothers, [@B128]). These early lesion studies and further neuropsychological data led Brothers to propose that the amygdala must be an essential part of "the social brain" in which the prefrontal (orbitofrontal cortex and cingulate gyrus) and temporal (inferotemporal and superior temporal sulcus) cortex are also involved (Brothers, [@B48]). However, more recently the role of the amygdala as an essential part of the "social brain" has been questioned (Amaral and Corbett, [@B14]; Amaral et al., [@B15]; Emery et al., [@B89]; Prather et al., [@B169]).

### Support from comparisons between autism and amygdala damage in humans

Even though people with amygdala damage may not be autistic in the classical sense of the DMS-IV, they do exhibit a few striking similarities with autistic patients regarding face perception and evaluation.

In a series of experiments, brain-damaged, amygdala-lesioned, and control subjects were compared in terms of their ability to recognize emotions conveyed through facial expressions. Adolphs and colleagues found that patients with either bilateral or unilateral damage to the amygdala exhibited impaired recognition of fear and in some cases also negative emotions such as anger or disgust when compared to controls or other brain-damaged subjects. The recognition of happy emotions was not impaired (Adolphs and Tranel, [@B3]; Adolphs et al., [@B7]; Adolphs et al., [@B9]). These patients were also impaired when they had to judge the trustworthiness of faces or when they had to identify more complex social emotions and mental states from facial expressions or merely the eye region, such as arrogance, guilt, admiration or flirtatiousness (Adolphs et al., [@B4]; Adolphs et al., [@B6]). Furthermore, amygdala-lesioned patients exhibited severe deficits in attributing mental states to others particularly when they acquired the lesion early in life, but not during adulthood (Shaw et al., [@B210]). Amygdala lesions also produce a deficit in gazing at the eyes of another person and instructing the patient to look directly at the eyes could restore the deficits in interpreting the information conveyed by the eyes (Adolphs et al., [@B8]).

It was argued that in particular an early insult to the amygdala might have severe consequences for the subsequent development of social networks in the brain, therefore social development in general und thus lead to autism (Bachevalier and Loveland, [@B24]; Schultz, [@B200]). For example, proper face perception and correct interpretation of emotional and mental states from face expressions is crucial for the successful navigation through the social world and virtually all normal human beings are experts in effortlessly recognizing faces and interpreting facial expressions (Carey, [@B49]; Diamond and Carey, [@B85]). This face expertise could be due to an innate tendency to attend to emotionally significant stimuli mediated by the amygdala. Already newborns show a natural tendency to preferentially attend to faces over other stimuli (Goren et al., [@B101]; Simion et al., [@B213]). This innate preference for faces has been postulated to be mediated by a subcortical visual system that passes information from the retina to the superior colliculus, the pulvinar nucleus of the thalamus, and from there to the amygdala (Pasley et al., [@B164]). Schultz ([@B200]) proposed that an insult to this system, and in particular to the amygdala alone, may profoundly interfere with socio-emotional development, because emotional significance might not be properly assigned. In fact, autistic infants display deviant eye gaze (resemblend to amygdala damage) and fail to attend to faces as early as in the first 6 months of life (Maestro et al., [@B140]). As a consequence they might never acquire normal face perception expertise.

Indeed, autistic people are selectively impaired in recognizing faces (Boucher and Lewis, [@B46]; Braverman et al., [@B47]; Davies et al., [@B81]; Hobson, [@B114]; Hobson et al., [@B115]; Klin et al., [@B127]; Langdell, [@B135]; ) and are also impaired in correctly recognizing facial expressions (Adolphs et al., [@B5]; Braverman et al., [@B47]; Hobson, [@B113]; Hobson et al., [@B116],a; Howard et al., [@B119]; Tantam et al., [@B225]; Weeks and Hobson, [@B235]). Direct comparisons on the same tests revealed that a few autistic subjects had similar impairments to amygdala-damaged people when rating faces expressing fear, disgust, and surprise (Adolphs et al., [@B5]). Furthermore, autistic people were reported to have severe problems in interpreting more complex social information such as judging the trustworthiness of others or interpreting the mental states of other people conveyed through both, the whole face or only the eyes, a pattern resembling amygdala damage (Adolphs et al., [@B5]; Baron-Cohen et al., [@B30]).

The amygdala also seems to be important in detecting and attributing social meaning in a much broader range of stimuli than just faces. In a now classical study, Heider and Simmel ([@B111]) demonstrated that normal subjects, when viewing animations that depict geometrical shapes on a plain, white background, spontaneously attribute social significance to the shapes (Heider and Simmel, [@B111]). In contrast, patients with amygdala lesions do not make such attributions, but describe the shapes in purely geometric terms (Heberlein and Adolphs, [@B110]) alike to autistic subjects who are also severely impaired in this task (Klin, [@B126]).

In summary, autistic subjects and amygdala-damaged patients do share some common features, most pronounced an impairment in correctly judging complex emotions and mental states from other peoples faces and in some cases also an impairment of recognizing simple negative emotions such as fear. Both patient groups have problems in correctly applying eye gaze to relevant stimuli (Adolphs et al., [@B8]; Howard et al., [@B119]). Finally, both patient groups have problems in performing spontaneous anthropomorphizations (Heberlein and Adolphs, [@B110]; Klin, [@B126]).

### Support from imaging studies

Three important fMRI studies have evaluated the involvement of the amygdala in autism focussing on face perception and evaluation of facial expressions. All of these studies consistently reported a hypo-activation of the amygdala (Baron-Cohen et al., [@B32]; Critchley et al., [@B78]; Pierce et al., [@B168]). For example, in the study of Baron-Cohen et al. ([@B32]) six subjects with autism were examined on a test of judging from the eye expression what another person might be feeling or thinking. While normal subjects showed increased activity in the prefrontal cortex, superior temporal temporal gyrus and amygdala on this task, autistic subjects did also activate fronto-temporal regions, but failed to activate the amygdala, thus giving rise to the term "amygdala theory of autism", but basically meaning "hypo-active amygdala theory of autism".

The "hyper-functioning" amygdala theory of autism
-------------------------------------------------

The current version of the amygdala theory of autism assumes a hypo-functional amydala, which leads to lack or inappropriateness of social behavior in autism. In this view, autists fail to assign emotional significance to their environment and for this reason are not interested in others, do not attend to faces, and fail to engage in normal social interaction. However, based on the result in the VPA model of autism and observations obtained in autistic humans, we propose that this view may be not correct and that quite to the contrary, the amygdala in the autistic individual may be hyper-reactive which leads to rapid excessive responses to socio-emotional stimuli. In this view, the autistic person would be overwhelmed with emotional significance and salience. As a consequence, the subject would want to avoid this emotional overload and would have to withdraw from situations, such as social encounters, which are rich in complex stimuli.

### Support from the VPA animal model and humans

Our studies on the VPA model of autism indicate that the amygdala is hyper-reactive, hyper-plastic and mediates hyper-fear, excessive fear memory generalization, and resistance to fear extinction (Markram et al., [@B141]). The current theory is also inconsistent with high anxiety levels in autism as well as the early developmental hypertrophy of the amygdala. Increased anxiety and phobias were not only noted by Kanner in 1943, but also in more recent studies in children with ASD (Evans et al., [@B90]; Gillott et al., [@B99]; Muris et al., [@B157]) and their relatives (Micali et al., [@B147]). For example, Muris et al. ([@B157]) investigated 44 children diagnosed with ASD and found 84.1% of the children met the criteria for at least one anxiety disorder, such as simple phobia (28%), social phobia (9%), agoraphobia (20%), panic disorder (4%), separation anxiety disorder (12%), avoidant disorder (8%), overanxious disorder (10%), and obsessivecompulsive disorder (5%). Rather than solely mediating the social deficits observed in autistic individuals, excessive and highly associate processing in the amygdala might be causal for the enhanced anxiety and fear so often reported in the autistic population, a view which has been brought forward recently (Amaral et al., [@B15]). Indeed enhanced levels of amygdala activation, possibly due to reduced inhibition, have been associated with increased anxiety and fear conditioning (Rodriguez Manzanares et al., [@B184]).

### The hyper-fear hypothesis

We suggest that enhanced fear and anxiety levels, mediated by a hyper-reactive and hyper-plastic amygdala, might underlie a core symptom of autism-impaired social behavior. A person daunted by anxiety and fears will normally not tend to interact with other people and will not dare to explore new situations and environments in the way a normal person does. A recent study screening for autism-like symptoms in children with mood and anxiety disorders, found that up to 62% of these kids fall into the autistic spectrum and might qualify for a possible ASD diagnosis (Towbin et al., [@B227]). Thus, increased fear processing might cause some of the autistic impairments in social and non-social situations. In further support of this view is that decreased amygdala activation has been linked to genetic hyper-sociability (Meyer-Lindenberg et al., [@B146]), whereas increased activation is observed in social avoidance and phobia (Stein et al., [@B219]), which further contradicts the current (hypo-active) version of amygdala theory of autism. Moreover, autistic children exhibit increased autonomic responses, indicative of enhanced amygdala activity (Corbett et al., [@B69]; Hirstein et al., [@B112]; Tordjman et al., [@B226]). Interestingly, we do also observe enhanced levels of the stress hormone coricosterone in the VPA-exposed rat offspring in the blood stream (K. Markram, unpublished data), suggesting increased stress levels. Post-traumatic stress disorder, in which the amygdala is hyper-active and hyper-responsivee to traumatic triggers, is accompanied by enhanced amygdala volumes (Damsa et al., [@B80]). Indeed, structural imaging studies revealed an accelerated amygdala growth during early infancy (Schumann et al., [@B205]; Sparks et al., [@B216]), suggesting that the amygdala of autistic children reaches adult size before adolescence, whereas the amygdala of typically developing children undergoes a progressive growth throughout adolescence. A hyper-trophism in the amygdala is also supported by some (but not all) structural imaging studies in autism (Abell et al., [@B1]; Howard et al., [@B119]; Schumann et al., [@B205]; Sparks et al., [@B216]).

It is, therefore, possible that the autistic person may perceive its surroundings not only as overwhelmingly intense due to hyper-reactivity of primary sensory areas, but also as aversive and highly stressful due to an overly reactive amygdala, which also makes quick and powerful fear associations with usually neutral stimuli. The autistic person may well try to cope with the intense and aversive world by avoidance.

Conclusion
==========

While many of the neuropathologies and symptoms observed in autism seem to resemble pieces of information in a scrambled puzzle, we proposed here a unifying hypothesis, which makes the first attempt to assemble the pieces into a coherent picture centered on excessive local circuit functionality. It has already been proposed that the autistic brain may be hyper-excitable due to excessive excitation or reduced inhibition (Hussman, [@B121]; Rubenstein and Merzenich, [@B186]), but our findings suggest that a more fundamental pathology is hype-reactivity which may be caused in a number of different ways. We reviewed here experimental findings obtained on the VPA rat model of autism that provide the first direct evidence for a unifying hypothesis. We propose that the core pathology of the autistic brain may be hyper-reactivity and hyper-plasticity of local neuronal circuits. On a perceptual and cognitive level, this excessive functioning of neuronal circuits may lead to an intensely perceived world, which may turn aversive if the amygdaloid complex is also affected. Many of the observed neuropathologies can be viewed as a consequence of hyper-reactive and hyper-plastic neural circuits, while many of the autistic symptoms may be re-interpreted in the light of an aversively intense world.

The *Intense World Syndrome* suggests that the autistic person is an individual with remarkable and far above average capabilities due to greatly enhanced perception, attention and memory. In fact it is this hyper-functionality, which could render the individual debilitated. This perspective of hyper-functionality offers new hope for pharmacological as well as behavioral treatments. For example, while most the commonly prescribed medication try to increase neuronal and cognitive functioning, we conclude that the autistic brain needs to be calmed down, learning needs to be slowed, and cognitive functions need to be diminished in order to re-instate proper functionality. In terms of behavioral treatments, the hyper-plasticity offers an immense scope for rehabilitation therapies that are based on excessive positive reward and comforting approaches and that avoid direct punishment, which may lead to a lockdown of behavioral routines. It may well turn out that successful treatments could expose truly capable and highly gifted individuals.
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